期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

多靶点抗肿瘤药应用与评价 被引量：1

Evaluation on the Rational Use of the Multi-target Anti-cancer Drug
下载PDF
导出
摘要 目的:多靶点抗肿瘤药临床合理应用概况。方法:收集国内外相关文献,从多靶点抗肿瘤药的作用机制、应用状况、不良反应等方面进行分析评价。结果及结论:多靶点抗肿瘤药目前已普遍应用于临床。 OBJECTIVE： To evaluate the rational use of the multi-target anti-cancer drug in the clinic.METHODS： The pertinent literature abroad were collected to analyze the use of multi-target anti-cancer drugs in the clinic in respect of action mechanism,application,ADRs etc.RESULTS CONCLUSION： The multi-target anti-cancer drug is widely used in the clinic.
作者 贡联兵
机构地区 解放军第
出处 《中国医院用药评价与分析》 2010年第1期7-9,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 多靶点抗肿瘤药 临床应用 评价 Multi-target anti-cancer drug Clinical application Evaluation
分类号 R979.1 [医药卫生—药品]
  • 相关文献

参考文献3

  • 1丁丽,程刚.多靶点抗肿瘤新药索拉非尼的药理作用及临床研究进展[J].药物不良反应杂志,2007,9(3):153-157. 被引量：12
  • 2Clark JW, Eder JP, Ryan D, et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43 -9006, in patients with advanced, refractory solid tumors[J]. Clin Cancer Res, 2005,11(15):5 472.
  • 3Strumberg D, Awada A, Hirte H, et al. Pooled safety analysis of BAY 43 - 9006 ( sorafenib ) monotherapy in patients with advanced solid tumors: Is rash associated with treatment outcome[ J]. Eur J Cancer,2006,42(4) : 548.

二级参考文献21

  • 1Wilhelm S, Chien DS. BAY 43-9006: preclinical data [J]. CurrPharmDes, 2002, 8(25):2255-2257.
  • 2Bos JL. ras oncogenes in human cancer: a review [J]. Cancer Res, 1989, 49(17):4682-4689.
  • 3Gamett MJ, Marais R. Guilty as charged:B-RAF is a human oncogene[J]. Cancer Cell, 2004, 6(4):313-319.
  • 4Beeram M, Patnaik A, Rowinsky EK. Raf: a strategic target for therapeutic development against cancer [J]. J Clin Oncol, 2005, 23(27):6771-6790.
  • 5Ferrara N, Gerber HP, Le Couter J. The biology of VEGF and its receptors[J]. Nat Med, 2003, 9(6):669- 676.
  • 6Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis [J]. Cancer Res, 2004, 64(19):7099-7109.
  • 7Wilhelm S, Housley T, Rong H, et al. The novel Raf inibitor BAY 43-9006 blocks signaling and proliferation in BRAF mutant and wildtype melanoma and colorectal tumor cell lines (abstract 106609) [J]. Proc Am Soc Clin Oncol, 2003, 22:203.
  • 8Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY43-9006 in patients with advanced refractory solid tumors[J]. J Clin Oncol, 2005, 23(5):965-972.
  • 9Clark JW, Eder JP, Ryan D, et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY439006, in patient with advanced, refractory solid tumor [J]. Clin Cancer Res, 2005, 11(15):5472-5480.
  • 10Moore M, Hirte HW, Siu L, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, adminis tered for 28 days on/7 days off in patients with advan ced, refractory solid tumors[J]. Ann Oncol, 2005, 16 (10): 1688-1694.

共引文献11

同被引文献2

引证文献1

中国医院用药评价与分析
2010年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部